Navigation Links
Biotechnology Value Fund, L.P. Announces Overwhelming Support to Remove the Board of Directors of Avigen, Inc. at Special Meeting of Stockholders
Date:3/27/2009

Concurs with Avigen's decision to return capital to stockholders through liquidation

A decisive victory for stockholder democracy

SAN FRANCISCO, March 27 /PRNewswire/ -- Biotechnology Value Fund, L.P. ("BVF"), today announced that stockholders of Avigen (Nasdaq: AVGN) voted overwhelmingly to remove the existing Board of Directors of Avigen and replace them with BVF's nominees. The vote took place earlier today at the special meeting of Avigen stockholders called by BVF. The preliminary vote count was approximately 58% in favor of removing Avigen's entire Board and 12% against removal.

Additionally, yesterday Avigen finally offered what BVF and stockholders have consistently sought but Avigen had steadfastly resisted: quantified downside protection. Specifically, Avigen announced yesterday that it would terminate merger discussions, implement a plan of liquidation and return at least $1.20 per share to all stockholders. BVF supports Avigen's decision, albeit a late one, and intends to work constructively with the Board to maximize the return to stockholders. Since the removal of the Board required the affirmative vote of 66 2/3% of the outstanding shares -- a very high hurdle -- the existing Board will remain in office and manage the liquidation.

Mark Lampert, BVF Founder and President stated, "This is a great day for stockholder democracy -- stockholders have spoken and their wishes have prevailed. Avigen's remaining capital will not be squandered but, instead, will be returned to stockholders so that each may decide how best to utilize their capital. For our part, we will look to reinvest the proceeds into the most promising small cap biotechnology companies that have the greatest potential to improve peoples' lives. In the current economic environment, the capital preserved through Avigen's
'/>"/>

SOURCE Biotechnology Value Fund, L.P.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InNexus Biotechnology Announces a Loan Facility of up to USD$2.5 Million
2. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
3. Biotechnology Value Fund Urges Stockholders to Remove and Replace Current Board of Avigen, Inc. in an Effort to Protect and Maximize Stockholder Value
4. Canadian Government Announces Funding for Leading Biotechnology Firms Project
5. InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
6. FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product
7. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
8. Yongye Biotechnology Announces Preliminary Results for Fiscal Year 2008
9. Yongye Biotechnology to Host Virtual Retail Road Show to Provide Overview of the Company in English and Mandarin
10. Yongye Biotechnology International to Expand its Network of Branded Stores
11. Biotechnology Value Fund, L.P. Requests Avigen Board to Provide Critical Information to Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Pursuit Solutions ( http://www.pursuit-solutions.com ... and services for Life Sciences sales and marketing ... of New Commercial Sales Models” by Peter Robinson, ... The article examines some innovative models used to ... tested in the pharmaceutical market. Robinson grades the ...
(Date:8/21/2014)... Gallus BioPharmaceuticals , LLC, ... manufacturing organization (CMO) announced today that it has ... company focused on the development of innovative approaches ... anti-prostate specific membrane antigen (PSMA) monoclonal antibody used ... the agreement the antibody will be produced in ...
(Date:8/21/2014)... August 21, 2014 On Wednesday of last ... to use Redox Signaling molecules, became available for purchase in ... , "The way that RENU 28 works is, if you ... down of the rate of cellular renewal within your body. ... increasing of that rate of cellular renewal. What RENU 28 ...
(Date:8/20/2014)... licensed to biotechnology firms has revealed early bottlenecks ... roadblocks, the researchers suggest that better communication of ... lead to faster commercialization down the road. , ... in university laboratories and licensed to biotechnology firms. ... have a high failure rate. But a new ...
Breaking Biology Technology:Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... 19 MAKO Surgical,Corp. today announced that it has filed ... Exchange Commission relating to a proposed,initial public offering of its ... sold by MAKO Surgical Corp. The,number of shares to be ... been determined. The Company intends to apply to have its ...
... AMSTERDAM, September 19 - IDF Launches ... IDF today issued the new global guideline ... glucose.(1) The guideline emphasizes,that people with diabetes should ... in order to optimize diabetes control and reduce ...
... BASEL, Switzerland, September 19 ,Arpida Ltd (SWX: ARPN) ... summary session of new antimicrobial agents at the ... (ICAAC) in,Chicago. ICAAC is a major scientific conference ... the world gather to discuss the,latest developments in ...
Cached Biology Technology:MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock 2The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes 2The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes 3Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 3
(Date:8/21/2014)... of American singles found that during sex with ... rates. On average, men experience orgasm 85.1 percent ... little difference. For women, however, orgasm occurrence is ... percent of the time during sex with a ... women,s sexual orientation, with lesbian women experiencing orgasm ...
(Date:8/21/2014)... a previously unknown process for harvesting energy and producing ... Penn State University scientist has discovered. The discovery lays ... growth, harvesting energy from the Sun, and understanding dense ... other lakes worldwide. A paper describing the discovery will ... of the journal Science on 21 August ...
(Date:8/21/2014)... ubiquitous skin fungus linked to dandruff, eczema and other ... to even further global reachesincluding Hawaiian coral reefs and ... vents. , A review in the scientific journal ... of the fungi of the genus Malassezia ... sequencing datasets from around the world. , University of ...
Breaking Biology News(10 mins):Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2
... South Korea, Jan. 8 Pixelplus Co.,Ltd. ... company in Korea that designs,develops, and markets ... today announced that it unveiled the "PM1002", ... image recognition,applications., The PM1002 integrates a ...
... 8, 2008) Adolescent girls who frequently eat meals ... pills, laxatives, or other extreme measures to control their ... Dianne Neumark-Sztainer, Ph.D., M.P.H., R.D., lead investigator of Project ... Minnesota School of Public Health. Neumark-Sztainer and Project ...
... Philadelphia, PA, January 8, 2008 Schizophrenia is a ... increased risk. Available antipsychotic medications treat some of ... only a subset of patients. Unfortunately, it is ... in any given individual with schizophrenia. John H. ...
Cached Biology News:Pixelplus Unveils Its PM1002 as A Practical Biometric Solution for Iris, Facial and Fingerprint Recognition 2Pixelplus Unveils Its PM1002 as A Practical Biometric Solution for Iris, Facial and Fingerprint Recognition 3U of M research finds disordered eating less common among teen girls who regularly eat family meals 2Genetic variant predicts antipsychotic response for schizophrenia patients by ethnicity 2
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
... Mucin 3 (MUC3) is a glycoprotein. ... a lesser extent in breast, lung and ... shows no cross-reaction with MUC1 and MUC2. ... human MUC3 Immunogen: MUC3 tandem ...
... CDX2, a member of the caudal-related ... that regulates both proliferation and differentiation in ... role in triggering cells towards the phenotype ... in the maintenance of the phenotype. Clone ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Biology Products: